Precision Targeting of Misfolded Proteins

Third Quarter 2026 Earnings Conference Call  Click Here

To view our PMN310 Scientific and Clinical Update (November 2026)   Click Here

Working to Transform the Lives of People with Neurodegenerative Diseases

Working to Transform the Lives of People with Neurodegenerative Diseases

Learn about the ProMIS mission and our team

About Our Company

Leveraging Our Proprietary Platform to Target Critical Drivers of Disease

Leveraging Our Proprietary Platform to Target Critical Drivers of Disease

Explore how we’re applying our EpiSelect™ Platform

Explore Our Platform

Advancing Next-Generation Therapies and Vaccines Designed to Maximize Selectivity

Advancing Next-Generation Therapies and Vaccines Designed to Maximize Selectivity

Read about our pipeline of innovative candidates

View Product Pipeline

Latest News

View All News

ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing

View Press Release

ProMIS Neurosciences to Participate in Upcoming Conferences in November

View Press Release

ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026

View Press Release
View All News